PLYMOUTH MEETING, Pa., April 30, 2025 /PRNewswire/ — INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it will be presenting at several upcoming conferences, including a fireside chat at the Citizens JMP Life Sciences Conference in New York. INOVIO will also present for the first time data on the long-term clinical effect of lead candidate INO-3107 at the American Broncho-Esophagological Association (ABEA) program at the Combined Otolaryngology Spring Meetings (COSM), the largest meeting of otolaryngologists in the U.S.
Citizens JMP Life Sciences Conference (NY)Date: May 8Time: 11:30am EDTFormat: Fireside Chat(audio webcast available here: https://wsw.com/webcast/jmp65/ino/1544620)
European Laryngological Society Annual Congress (Warsaw, PL)Date: May 9
Oral presentation: DNA immunotherapy, INO-3107, generates targeted immunologic response and results in surgery reduction for 81% of adults with recurrent respiratory papillomatosis in year 1
American Society of Gene and Cell Therapy (New Orleans, LA)Date: May 13
Poster Abstract Session: Successful Treatment of Recurrent Respiratory Papillomatosis with INO-3107 is Irrespective of Papilloma Microenvironment and Molecular Subtype
ABEA at COSM (New Orleans, LA)Date: May 15Oral Presentation: DNA Immunotherapy (INO-3107) Durability and Long-Term Clinical Effect in Treatment of Recurrent Respiratory Papillomatosis Caused by HPV 6 & 11
Available abstracts will be shared on INOVIO’s website following presentations. An audio replay of the Citizens JMP webcast will be available for 90 days after the event.
About INOVIOINOVIO is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases. INOVIO’s technology optimizes the design and delivery of innovative DNA medicines that teach the body to manufacture its own disease-fighting tools. For more information, visit www.inovio.com.
ContactsMedia: Jennie Willson, (267) 429-8567, [email protected]
Investors: Peter Vozzo – ICR Healthcare, (443) 213-0505, [email protected]
SOURCE INOVIO Pharmaceuticals, Inc.
